Overview

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard therapies likely to benefit the subject.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborators:
IQVIA
Iqvia Pty Ltd
Merck Sharp & Dohme Corp.
Treatments:
Olaparib